Incorporating Imaging Markers of Brain Health in Modeling of Functional Outcome After Acute Ischemic Stroke: A Quantitative Comparison Study

Erik Lindgren[1,2,3]; Luca Angeleri[1]; Martin Bretzner[4]; Anna K. Bonkhoff[1]; Christina Jern[5,6]; Arne G Lindgren[7]; Jane Maguire[8]; Robert W. Regenhardt[1]; Natalia S. Rost[1]; Markus D. Schirmer[1] and the MRI-GENIE and GISCOME Investigators

1. Department of Neurology, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2. Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg
3. Department of Neurology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
4. Lille University, Inserm, CHU Lille, U1172—LilNCog—Lille Neuroscience & Cognition, France
5. Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
6. Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
7. Department of Neurology, Skåne University Hospital; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden
8. University of Technology Sydney, Sydney, Australia

Corresponding Author:
Erik Lindgren, MD, PhD
JPK Stroke Research Center, Massachusetts General Hospital,
175 Cambridge St,
02114, Boston, MA, US
erik.lindgren@neuro.gu.se
phone: +46 702735465

Number of references: 18

Number of tables: 2

Number of figures: 2

Supplemental data: eTable 1, eTable 2, Appendix

Key words: brain health; stroke; acute ischemic stroke; outcome; imaging;

Abstract
Background and Objectives:
Brain health facilitates resilience to withstand detrimental effects of brain disease, but is challenging to assess in the time-sensitive setting of acute ischemic stroke (AIS). In this international observational multicenter study, we compare quantitative MRI markers of structural brain health in their ability to predict functional outcome after AIS.

Methods:
We included AIS patients from the international MRI-GENIE study (multicenter; 2003-2011) with acute T2-FLAIR imaging. Automated pipelines estimated white matter hyperintensity volume (WMHv), brain volume, and intracranial volume (ICV). We normalized WMHv by individual brain volume, creating WMH load for each patient. Assessed brain health markers included: brain parenchymal fraction (brain volume relative to ICV); radiomics derived brain age (based on an ElasticNet linear regression model); brain reserve (normal appearing brain volume [brain volume minus WMHv] relative to ICV), and effective Reserve (eR, latent variable based on age, WMH load [WMHv and brain volume). We added the markers to a clinical reference model (including age, sex, diabetes type 2, hypertension, NIHSS, atrial fibrillation and prior stroke), comparing model performances between separate multivariable regression models in their prediction of unfavorable outcome (90-day modified Rankin Scale score 3-6), using Bayesian Information Criterion (BIC).

Results:
We analyzed 2,303 patients (median age 66 years, 46% female, 27% unfavorable outcome) after excluding 357/2,660 patients (13.4%) due to missing follow-up data. Comparison using BIC provided strong statistical evidence (ΔBIC > 6) for all four models using a brain health marker to outperform the clinical reference model (BIC=2354.9). The eR model showed the lowest BIC value (BIC=2318.4), providing very strong (ΔBIC > 10) statistical evidence to outperform all other models. The model utilizing radiomics derived brain age showed the second lowest BIC value (BIC=2329.3), providing very strong (ΔBIC > 10) statistical evidence to outperform all other models except the eR model.

Discussion:
Incorporating quantitative MRI markers of brain health in predictive models enhance personalized outcome prognostication after AIS. Our results suggest eR as a viable marker for future studies investigating structural brain health and ischemic stroke.

Introduction

Brain health facilitates resilience to withstand detrimental effects of brain disease, and is a prioritized research area by international organizations.[1] As a holistic and evolving concept, brain health encompasses both absence of disease and the brain's optimal functioning during a lifespan, even if a disease is present.[1,2] Preserving and understanding threats to brain health is essential for preventing and enhancing resilience against age-related neuropathology. [3]

While stroke is the leading global contributor to long-term disability, the importance of brain health for functional outcome after acute ischemic stroke (AIS) remains relatively underexplored.[4] However, recently developed automated evaluation of magnetic resonance imaging (MRI) markers at time of admission presents opportunities for prompt quantification of structural brain health markers, with the potential to inform personalized clinical decision making even in acute settings. The purpose with this study was to investigate whether incorporation of MRI-markers of structural brain health improve modeling of functional outcome after acute ischemic stroke.

We aimed to compare four quantitative MRI markers of brain health that can be assessed in the acute stroke setting using automated deep learning enabled pipelines and routinely obtained MRI sequences. In a large multicenter clinical cohort, we compared these markers to each other and to a reference model with only clinical variables in terms of the ability to predict functional outcome after AIS.

Methods

This report adheres to international guidelines for reporting observational studies.[5]

Standard protocol approval, registration and patient consent
Participating centers received permission from local authorities and ethics committees to collect observational data and obtained written informed consent from participants or their surrogates at time of enrollment, when required under applicable laws.

Participants
We analyzed data from the MRI-GENetics Interface Exploration (MRI-GENIE) study, an international AIS cohort (multicenter, 2003-2011). Details of the MRI-GENIE cohort have been described previously.[6] Patients with acute MRI including T2-Fluid-attenuated inversion recovery (FLAIR) sequences were eligible. Participants aged 90 years and older were aggregated into a single age category in accordance with the Health Insurance Portability and Accountability Act (HIPAA).

Phenotypical data
Clinical characteristics (stroke severity according to National Institutes of Health Stroke Scale [NIHSS]), demographics and medical history were collected at acute hospital admission. Functional outcome was assessed at approximately 90 days post-stroke, using the modified Rankin Scale (mRS), a 7-grade ordinal scale ranging from 0 representing no symptoms, to 6 representing death.[7] We defined unfavorable outcome as mRS score 3-6.[8]

122
Neuroimaging
Neuroimaging was obtained mostly within 48 hours of acute hospital admission (median
2 days, IQR 1-4 days) as part of routine care using AIS protocols. All images were either
captured on 1T, 1.5T or 3T scanners (General Electric Medical Systems, Philips Medical
Systems, Siemens, Toshiba, Marconi Medical Systems, Picker International Inc.). We
automatically assessed white matter hyperintensity (WMH) volume, intracranial volume
(ICV) and brain volume (combined gray matter and white matter parenchymal volumes)
based on FLAIR, utilizing pipelines developed for MRI acquired in the acute clinical
setting of AIS patients.[9,10] Results were manually reviewed, and failed segmentations,
e.g. due to image artifacts, were excluded. All volumes (WMH volume, brain volume)
were calculated multiplying number of voxels by voxel size. We normalized WMH
volume by individual brain volume, creating WMH load for each patient.
135
MRI brain health markers
We assessed four neuroimaging markers of brain health described in the literature: 1)
brain parenchymal fraction (BPF)[11] – brain volume relative to ICV; 2) radiomics derived
brain age (BA)[12] – based on an ElasticNet linear regression model; 3) brain reserve
(BR)[13] – normal appearing brain volume (brain volume minus WMH volume) relative to
ICV; and 4) effective Reserve (eR)[14] – a latent variable estimated based on the
observed variables age, WMH load and brain volume. To prevent overfitting, pathway
coefficients used to estimate eR in the study cohort were derived from a separate
cohort.[14]
145
Statistical analysis
We report continuous data as medians with interquartile ranges (IQR) and dichotomous
data as proportions of investigated patients. We assessed normal distributions using
Shapiro-Wilk test and applied logit transformation on WMH load for normality. We
excluded patients with incomplete data (see Figure 1). Number of included patients from
each participating center appear in eTable 2.
152
We defined a clinical reference logistic regression model based on biological plausibility
and consistent reporting as independent predictors for unfavorable outcome (mRS
score 3-6 at 90 days). The model included clinical variables such as age, sex, diabetes
mellitus type 2, hypertension, atrial fibrillation, history of prior stroke and stroke severity
(NIHSS). To this reference model, MRI brain health markers were added creating four
brain health models while controlling for multicollinearity using variance inflation factor
(VIF). To mitigate inclusion of highly correlated variables into the same model,
adjustment for age was only conducted if not used to determine the respective brain
health marker (see Table 2).
162
We compared the predictive performances between these four brain health models and
the reference model in terms of goodness-of-fit using Bayesian Information Criterion
(BIC).[15] A lower BIC value represents relatively superior model performance, and the
methodology involves penalizing to more complex models to minimize risk for
overfitting. In model selection analysis, evidence levels for statistical differences are

considered weak, positive, strong or very strong for differences in BIC (ΔBIC) values
larger than 0, 2, 6 and 10 respectively.[15] We further calculated the area under the
precision-recall curve (PR-AUC) with 95% CI using 10-fold cross-validation with 100
iterations. In each iteration, test cohorts were formed by randomly selecting 100 positive
and negative outcomes defined as mRS 3-6 and 0-2 respectively. The remaining
dataset (full dataset - test cohort), were used to train the models. The PR-AUC
resembles the traditional receiver operating characteristic AUC, while being more
accurate in unbalanced datasets.[16] As the outcome measured in this cohort was
unbalanced, with approximately one fourth of the patients categorized as having an
unfavorable outcome, PR-AUC was used instead of ROC-AUC. Mean PR-AUC values
and corresponding 95% CI were calculated in the test cohorts from stored predicted
probabilities of PR-AUC integrals. P-values were calculated using Mann Whitney U
tests with significance level set to p<0.05.
181
182 In a subanalysis, we conducted the same analyses in more complex models,
183 additionally including comprehensive adjustments also for WMH load and brain volume
184 if not used to determine the respective brain health marker (see eTable 1).
185
186 All analyses were performed using R (version 4.4.1; R Foundation for Statistical
187 Computing) with significance level set to p<0.05.
188
189 *Data Availability*
190 Data, methods and materials will be made available for the purpose of reproducing the
191 results upon reasonable request to the authors, subject to approval by the local
192 Institutional Review Boards.
193
Results
Study Cohort and Baseline Characteristics
We analyzed 2,660 patients with complete baseline data (median age 67 years, 46%
female), of which 357 (13.4%) were excluded due to missing follow-up data (see Figure
1). Baseline characteristics stratified by outcome categories appear in Table 1. Baseline
characteristics included hypertension (71%), diabetes mellitus type 2 (10%), atrial
fibrillation (18%) and history of prior stroke (16%). Median NIHSS score was 3 (IQR 1-
6), median brain volume 1250 cc (IQR 1140-1360) and median WMH volume 3.95 cc
(IQR 1.25-9.85). At 90 days, 626 patients (27%) had a mRS score of 3-6.
203
204 *Comparison of Model Performance with and without Brain Health Markers*
205 Investigated models are presented with their corresponding BICs and PR-AUC values in
206 Table 2 and graphically with adjusted odds ratios (aORs) and 95% CI in Figure 2.
207 Comparison using BIC provided strong statistical evidence (ΔBIC > 6)[15] for all four
208 models including a brain health marker to outperform the reference model.
209
The model utilizing eR showed the lowest BIC value (BIC=2318.4), providing very
strong (ΔBIC > 10) statistical evidence to outperform all other investigated models (see
Table 2 and Figure 2).[15] BA showed the second lowest BIC value (BIC=2329.3),
providing very strong (ΔBIC > 10) statistical evidence to outperform all other models

except the eR model. The PR-AUC value was significantly higher in the eR (0.763, 95%
CI 0.681-0.832, p=0.038) compared to the reference model (0.753, 95% CI 0.668-
0.827), but no significant differences were observed compared to the BA, BPF or BR
models. VIF values indicated no significant multicollinearity for variables included in the
investigated models respectively.
219
Subanalysis with Comprehensive Model Adjustments
Results from the subanalysis are presented with the models' corresponding BICs and
PR-AUC values in eTable 1. Model comparison using BIC provided very strong
statistical evidence for eR (BIC=2318.4, ΔBIC > 10) to outperform BPF (BIC=2334.9),
BR (BIC=2343.7) and the reference models (BIC=2329.0) and strong statistical
evidence to outperform the BA model (BIC=2324.9, ΔBIC > 2). The model utilizing BA
outperformed the reference model (ΔBIC > 2) and the BPF and BR models (ΔBIC > 10).
In the subanalysis, we observed no difference in PR-AUC values between any of the
brain health models, as compared to the reference model.
229
230 **Discussion**
231 In this international observational multicenter study, we demonstrate that the addition of
232 neuroimaging brain health markers enhances modeling of functional outcome after AIS.
233 The model utilizing effective Reserve (eR) outperformed the other investigated models,
234 highlighting eR as a promising marker to quantify brain health in clinical settings.
235
Our findings are in line with previous studies showing the importance of incorporating
brain health markers to predict outcomes after neurological diseases.[11-14,17] Mostly
smaller cohorts have explored the use of brain health markers specifically in stroke,
often relying on high quality imaging data and manual imaging assessment.[11,17,18] Here,
we utilize automatized pipelines to quantify structural brain health, enabling translation
into the routine acute stroke setting and bringing the holistic concept of *brain health in*
stroke closer to clinical implementation. From a clinical perspective, such markers may
complement established clinical and imaging predictors by providing an estimate of the
brain's capacity to tolerate ischemic injury or recovery potential, thereby refining
individualized prognostic assessment in the acute and subacute stroke settings. While
the methodology used to extract the neuroimaging markers are also applicable to
modern ischemic stroke patient cohorts, prospective validation in contemporary cohorts
is required before routine clinical implementation can be recommended.
249
Both eR and radiomics derived BA outperformed the other models, with substantially
lower BICs and the eR model additionally showed higher PR-AUC, compared to the
clinical reference model (Table 2). While statistically significant, the numerical
differences in PR-AUC were relatively modest and implications for prognostication, risk
stratification and trial designs needs to be investigated in future work. The results were
consistent regarding BICs, but not PR-AUCs, when adjusting more comprehensively
also for WMH load and brain volume (eTable 1). A possible explanation is that BPF and
BR have not been specifically developed to quantify brain health in stroke populations
and BR do not comprehend present pathology. The latent variable approach used to
estimate eR and the radiomics approach to calculate BA may capture more nuanced

signals of brain health, as compared to markers of brain volume, WMH volume and ICV,
combined or alone.
262
While brain health is a multidimensional concept encompassing several domains, the
current study focused on markers of structural brain health that are directly available at
time of admission. This study provides evidence for associations between the
investigated measures of brain health and functional outcome, however, causal
relationships remain to be explored. Future studies are needed to determine whether
brain health is an independent predictor of functional outcomes or, instead, a
quantitative measure of resilience that reflects the capacity to mitigate the negative
effects of brain injury.
271
Strengths of this study include the large international multicenter setting with
standardized automated central adjudication of imaging to quantify structural brain
health. Several limitations warrant comment. First, study participants were enrolled
between 2003-2011, detailed treatment data were not available and included patients
largely presented with mild to moderate stroke severity. The cohort may hence not be
fully representative of severe stroke and current stroke care, involving more inclusive
and advanced reperfusion therapies. The generalizability of our findings to
contemporary stroke patient cohorts should be interpreted with caution. Second,
investigated brain health markers are dependent on MRI which is not broadly available
in acute stroke care worldwide. Third, only structural measures of brain health were
considered, and we acknowledge that the limited available sequences in our data set
did not allow for taking other imaging markers such as cerebral microbleeds,
macrohemorrhages and measures of structural connectivity into account. Fourth, data
on timing of stroke symptom onset, stroke phenotypes were limited, and brain health
markers were assessed after stroke onset. Acute ischemic changes potentially influence
the estimation of volumetric measures and WMH segmentation. However, the pipelines
used have been developed in stroke patient cohorts and specifically designed not to
misinterpret ischemic hyperintensities as WMH. Further, according to the study protocol,
only patients with acute stroke were consecutively included at time of their acute
hospital admission, supporting a restricted time between stroke onset and image
assessment and our results to reflect mostly acute strokes.[6] Fifth, data on premorbid
mRS was not available. Instead, we included prior stroke as a proxy for premorbid
status and adjusted for several comorbidities in the multivariate models. Cognitive
aspects of brain health and a wider variety of outcomes, e.g. those obtained via patient
reported outcome measures (PROMs), remain to be investigated. Next steps should
further investigate how AIS or modifiable risk factors influence brain health and whether
brain health modifies the outcome after stroke.
299
300   In conclusion, our results emphasize the importance of incorporating MRI measures of
301   brain health for personalized outcome prognostication after AIS and suggest eR as a
302   viable marker for future studies investigating brain health and stroke.
303
Study Funding

Research reported in this publication was supported by the Swedish Research Council
(2023-06531), the Swedish Heart Lung Foundation (no. 20230904, 2024135125), The
Swedish Brain Foundation, The Swedish Government (under the "Avtal om
Läkarutbildning och Medicinsk Forskning, ALF"), Lund University, Region Skåne, The
FGS Fang Foundation, The Fremasons Lodge of Instruction Eos in Lund, The Swedish
Stroke Association, AI Cures Grant Award, and the National Institute on Aging (NIA
R21AG083559).

Disclosure

NSR is supported by NINDS U19NS115388 and the MGB AI Cures Grant Award. AGL is
national leader for Sweden for one ongoing stroke trial, local PI for the StrokeCLOSE
study, Co-chairs the Global Alliance for International Stroke Genetics Consortium of
Acute and Long-term Outcome studies, is Co-PI for The Genetics of Ischaemic Stroke
Functional Outcome (GISCOME), and reports personal fees from Arega, Bayer, Astra
Zeneca, BMS Pfizer, and Novo Nordisk. RWR serves on a DSMB for a trial sponsored
by Rapid Medical, serves as site PI for studies sponsored by MicroVention and
Penumbra, and receives research grant support from NIH (NINDS R25NS065743),
Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation. MDS
is supported by AI Cures Grant Award, Heitman Stroke Foundation, and NIA
R21AG083559.

Acknowledgements

The authors thank participating patients and their families and the MRI-GENIE and
GISCOME investigators.

Research reported in this publication was supported by the National Institute On Aging
of the National Institutes of Health under Award Number R21AG083559. The content is
solely the responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health. This manuscript is the result of funding in
whole or in part by the National Institutes of Health (NIH). It is subject to the NIH Public
Access Policy. Through acceptance of this federal funding, NIH has been given a right
to make this manuscript publicly available in PubMed Central upon the Official Date of
Publication, as defined by NIH.

Figure 1. Flow Chart of Included Patients

339
340 *Abbreviations: MRI-GENIE - MRI-GENetics Interface Exploration study; NIHSS – National Institutes*
341 *of Health Stroke Scale; mRS – modified Rankin Scale*
342

Figure 2. Comparison of Models to Predict Functional Outcome (mRS 3-6) at 90 days After Acute Ischemic Stroke

Model		BIC	PR-AUC (95% CI)	p-value
●	Brain Age	2329	0.758 (0.688-0.833)	0.385
●	Brain Parenchymal Fraction	2348	0.756 (0.669-0.833)	0.472
●	Brain Reserve	2344	0.757 (0.671-0.833)	0.353
●	effective Reserve	2318	0.763 (0.681-0.832)	0.038
●	Ref	2355	0.753 (0.668-0.827)	Ref

347
348
349
Abbreviations: BIC - Bayesian Information Criterion; PR-AUC – Precision Recall Area Under Curve;
Ref – Reference; CI – Confidence Interval; BA – radiomics derived Brain Age; BPF – Brain
Parenchymal Fraction; BR – Brain Reserve; eR – effective Reserve; NIHSS – National Institutes of
Health Stroke Scale; mRS – modified Rankin Scale; DM – Diabetes Mellitus Type 2; HTN –
Hypertension.

355
Each brain health model and its adjusted odds ratio appear as a colored dot and corresponding 95%
confidence interval line. Models were adjusted for age, sex, prior stroke, atrial fibrillation, NIHSS,
hypertension, diabetes type 2 (see Table 2 for variables included in each model), Lower BIC indicate
better model performance. In model selection analysis, evidence levels for statistical differences are
considered Weak, Positive, Strong or Very strong for differences in BIC (ΔBIC) larger than 0, 2, 6
and 10 respectively. PR-AUC values for each model including a quantitative MRI marker of brain
health are compared to a reference model with only clinical variables using Mann Whitney U test.
363

364 **Table 1. Characteristics of 2,303 Patients with Acute Ischemic Stroke**

Variable	All, n=2,303	mRS 0-2, n=1,677 (73%)	mRS 3-6, n=626 (27%)	p-value
Demographics				
Age, years (median, [IQR])	67.0 (57.0-77.0)	65.2 (54.7-74.4)	74 (63.6-81.0)	<0.001
Sex (F; [%])	1047 (45.5)	705 (42.0)	341 (54.6)	<0.001
Cardiovascular Risk Factors				
Diabetes mellitus type 2 (%)	226 (9.8)	152 (9.1)	74 (11.8)	0.057
Hypertension (%)	1639 (71.2)	1142 (68.1)	497 (79.4)	<0.001
Atrial Fibrillation (%)	408 (17.7)	251 (15.0)	157 (25.1)	<0.001
Prior Stroke (%)	364 (15.8)	221 (13.2)	143 (22.8)	<0.001
Presentation				
NIHSS (median, [IQR])	3 (1-6)	2 (1-5)	5 (3-11)	<0.001
Imaging Characteristics				
Brain volume, cc (median, [IQR])	1250 (1140-1360)	1270 (1170-1380)	1190 (1090-1310)	<0.001
Intracranial volume, cc (median, [IQR])	1610 (1500-1710)	1620 (1510-1730)	1570 (1460-1680)	<0.001
White matter hyperintensity volume, cc (median, [IQR])	3.95 (1.25-9.85)	3.30 (1.04-8.62)	6.05 (2.51-13.5)	<0.001
Brain Health Markers				
Brain Parenchymal Fraction (%, median, [IQR])	78.6 (75.0-81.6)	79.0 (75.9-81.9)	76.8 (72.8-80.4)	<0.001
Brain Age (median, [IQR])	66.0 (56.0-73.9)	63.7 (54.5-72.0)	71.1 (62.8-77.0)	<0.001
Brain Reserve (%, median, [IQR])	78.0 (74.3-81.2)	78.5 (75.4-81.5)	76.0 (72.1-80.0)	<0.001
Effective Reserve (A.U., median, [IQR])	-0.347 (-0.863-0.112)	-0.258 (-0.733-0.238)	-0.715 (-1.15--0.262)	<0.001

365
366
367 *Abbreviations: SD – standard deviation; IQR – Interquartile range; NIHSS – National Institutes of*
368 *Health Stroke Scale; cc – cubic centimeters; mRS – modified Rankin Scale; A.U. – Arbitrary Units*
369

370 **Table 2. Comparison of Investigated Models Including a Quantitative MRI Marker**
371 **of Brain Health to Predict Functional Outcome defined as mRS 3-6 at 90 Days**
372 **After Acute Ischemic Stroke**

Model	Included variables	aOR	95% CI	P-value	BIC	PR-AUC (95% CI)
Reference	Age	1.04	1.03 - 1.05	<0.001	2354.9	0.753 (0.668 - 0.827) p-value: N/A
	Female	1.47	1.20 - 1.81	<0.001		
	Diabetes Type 2	1.32	0.96 - 1.82	0.087		
	Hypertension	1.30	1.02 - 1.70	0.037		
	NIHSS	1.15	1.13 - 1.17	<0.001		
	Atrial Fibrillation	1.12	0.86 - 1.45	0.385		
	Prior Stroke	1.92	1.48 - 2.48	<0.001		
Brain Parenchymal Fraction (BPF)	BPF, %	0.96	0.94 - 0.98	<0.001	2347.9	0.756 (0.669 - 0.833) p-value: 0.472
	Age	1.03	1.02 - 1.04	<0.001		
	Female	1.49	1.22 - 1.83	<0.001		
	Diabetes Type 2	1.38	0.99 - 1.90	0.053		
	Hypertension	1.26	0.99 - 1.62	0.066		
	NIHSS	1.15	1.13 - 1.18	<0.001		
	Atrial Fibrillation	1.13	0.87 - 1.46	0.371		
	Prior Stroke	1.83	1.41 - 2.37	<0.001		
Brain Age (BA)	BA	1.05	1.04 - 1.06	<0.001	2329.3	0.758 (0.688 - 0.833) p-value: 0.385
	Female	1.59	1.29 - 1.95	<0.001		
	Diabetes Type 2	1.27	0.92 - 1.75	0.147		
	Hypertension	1.27	1.00 - 1.64	0.057		
	NIHSS	1.15	1.13 - 1.17	<0.001		
	Atrial Fibrillation	1.17	0.90 - 1.51	0.23		
	Prior Stroke	1.81	1.39 - 2.34	<0.001		
Brain Reserve (BR)	BR, %	0.95	0.93 - 0.97	<0.001	2343.7	0.757 (0.671- 0.833) p-value: 0.353
	Age	1.03	1.02 - 1.04	<0.001		
	Female	1.50	1.22 - 1.84	<0.001		
	Diabetes Type 2	1.36	0.98 - 1.87	0.064		
	Hypertension	1.25	0.98 - 1.61	0.077		
	NIHSS	1.15	1.13 - 1.17	<0.001		
	Atrial Fibrillation	1.13	0.87 - 1.46	0.362		
	Prior Stroke	1.82	1.40 - 2.36	<0.001		
effective Reserve (eR)	eR	0.39	0.33 - 0.47	<0.001	2318.4	0.763 (0.681 - 0.832) p-value: 0.038
	Female	1.06	0.85 - 1.31	0.626		
	Diabetes Type 2	1.25	0.90 - 1.73	0.172		
	Hypertension	1.19	0.93 - 1.54	0.164		
	NIHSS	1.15	1.13 - 1.18	<0.001		
	Atrial Fibrillation	1.19	0.92 - 1.53	0.193		

| | Prior Stroke | 1.74 | 1.34 - 2.25 | <0.001 | | |

376 *Abbreviations: aOR – adjusted Odds Ratio; BIC – Bayesian Information Criterion; CI – Confidence*

377 *Interval; PR-AUC – Area Under the Precision Recall Curve; NIHSS – National Institutes of Health*

378 *Stroke Scale; WMH – white matter hyperintensity; BPF – Brain Parenchymal Fraction; BA –*

379 *Radiomics derived Brain Age; BR – Brain Reserve; eR – effective Reserve.*

382 **Appendix. MRI-GENIE Study Group Members**

Name	Location	Role	Contribution
Daniel Woo, MD	Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, and Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, NY, USA	Coinvestigator, Site PI	Data acquisition
Natalia S. Rost, MD, PhD	J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA	Author, Site PI	Revision of the manuscript for content, including medical writing for content, Major role in the acquisition of data, analysis or interpretation of data
Jordi Jimenez-Conde, MD	Department of Neurology, Neurovascular Research Group (NEUVAS), IMIMHospital del Mar (Institut Hospital del Mar d'Investigacions M`ediques), Universitat Autonoma de Barcelona, Barcelona, Spain	Coinvestigator, Site PI	Data acquisition
Christina Jern, MD, PhD	Institute of Biomedicine, Department of Laboratory Medicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Genetics and Genomics, Gothenburg, Sweden	Author, Site PI	Revision of the manuscript for content, including medical writing for content, Major role in the acquisition of data, analysis or interpretation of data
Arne G. Lindgren, MD, PhD	Section of Neurology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden	Author, Site PI	Revision of the manuscript for content, including medical writing for content, Major role in the acquisition of data,

Name	Location	Role	Contribution
			analysis or interpretation of data
Robin Lemmens, MD	KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium; VIB, Vesalius Research Center, Laboratory of Neurobiology, University Hospitals Leuven, Department of Neurology, Leuven, Belgium	Coinvestigator, Site PI	Data acquisition
Turgut Tatlisumak, MD, PhD	Department of Neurology, Helsinki University Hospital, Helsinkni, Finland, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden	Coinvestigator, Site PI	Data acquisition
Ramin Zand, MD	Department of Neurology, Geisinger, Danville, PA	Coinvestigator, Site PI	Data acquisition

383
384 **GISCOME Study Group Members**

Name	Location	Role	Contribution
Christina Jern, MD, PhD	Institute of Biomedicine, Department of Laboratory Medicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Genetics and Genomics, Gothenburg, Sweden	Author, Study Group PI and representative	Revision of the manuscript for content, including medical writing for content, Major role in the acquisition of data, analysis or interpretation of data
Arne G. Lindgren, MD, PhD	Section of Neurology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden	Author, Study Group PI and representative	Revision of the manuscript for content, including medical writing for content, Major role in the acquisition of data, analysis or interpretation of data
Jane Maguire, PhD, BA, BNurs (Hons)	University of Technology Sydney, Sydney, Australia	Author, Study Group PI and representative	Revision of the manuscript for content, including medical writing for content, Major role in

			the acquisition of data, analysis or interpretation of data

385
386
387

388
References
1.   Rost NS, Salinas J, Jordan JT, et al. The Brain Health Imperative in the 21st
Century-A Call to Action: The AAN Brain Health Platform and Position Statement.
Neurology. Sep 26 2023;101(13):570-579. doi:10.1212/wnl.0000000000207739
2.   Gorelick PB, Furie KL, Iadecola C, et al. Defining Optimal Brain Health in Adults:
A Presidential Advisory From the American Heart Association/American Stroke
Association. *Stroke*. Oct 2017;48(10):e284-e303. doi:10.1161/str.0000000000000148
3.   Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke
Statistics: A Report of US and Global Data From the American Heart Association.
Circulation. 2024/02/20 2024;149(8):e347-e913. doi:10.1161/CIR.0000000000001209
4.   Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years
lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life
expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and
811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of
Disease Study 2021. *Lancet*. May 18 2024;403(10440):2133-2161. doi:10.1016/S0140-
6736(24)00757-8
5.   von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
statement: guidelines for reporting observational studies. *Lancet*. Oct 20
2007;370(9596):1453-7. doi:10.1016/s0140-6736(07)61602-x
6.   Giese AK, Schirmer MD, Donahue KL, et al. Design and rationale for examining
neuroimaging genetics in ischemic stroke: The MRI-GENIE study. *Neurol Genet*. Oct
2017;3(5):e180. doi:10.1212/nxg.0000000000000180
7.   Banks JL, Marotta CA. Outcomes Validity and Reliability of the Modified Rankin
Scale: Implications for Stroke Clinical Trials. *Stroke*. 2007/03/01 2007;38(3):1091-1096.
doi:10.1161/01.STR.0000258355.23810.c6
8.   Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient
ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry*. Dec
1991;54(12):1044-54. doi:10.1136/jnnp.54.12.1044
9.   Alhadid K, Regenhardt RW, Rost NS, Schirmer MD. Brain volume is a better
biomarker of outcomes in ischemic stroke compared to brain atrophy. *Frontiers in
Stroke*. Oct 29 2024;3doi:10.3389/fstro.2024.1468772
10.   Schirmer MD, Dalca AV, Sridharan R, et al. White matter hyperintensity
quantification in large-scale clinical acute ischemic stroke cohorts - The MRI-GENIE
study. *Neuroimage Clin*. 2019;23:101884. doi:10.1016/j.nicl.2019.101884
11.   Bu N, Khlif MS, Lemmens R, et al. Imaging Markers of Brain Frailty and Outcome
in Patients With Acute Ischemic Stroke. *Stroke*. Mar 2021;52(3):1004-1011.
doi:10.1161/strokeaha.120.029841
12.   Bretzner M, Bonkhoff AK, Schirmer MD, et al. Radiomics-Derived Brain Age
Predicts Functional Outcome After Acute Ischemic Stroke. *Neurology*. Feb 21
2023;100(8):e822-e833. doi:10.1212/wnl.0000000000201596
13.   Zijlmans JL, Lamballais S, Lahousse L, et al. The interaction of cognitive and
brain reserve with frailty in the association with mortality: an observational cohort study.
The Lancet Healthy Longevity. 2021;2(4):e194-e201. doi:10.1016/S2666-
7568(21)00028-3

14.   Schirmer MD, Alhadid K, Regenhardt RW, Rost NS. Quantifying Brain Health in
Acute Ischemic Stroke Through Effective Reserve. *Neurology*. Mar 11
2025;104(5):e210180. doi:10.1212/wnl.0000000000210180
15.   Raftery AE. Bayesian model selection in social research. *Sociological*
methodology. 1995:111-163.
16.   Boyd K, Eng KH, Page CD. Area under the Precision-Recall Curve: Point
Estimates and Confidence Intervals. Springer Berlin Heidelberg; 2013:451-466.
17.   Appleton JP, Woodhouse LJ, Adami A, et al. Imaging markers of small vessel
disease and brain frailty, and outcomes in acute stroke. *Neurology*. Feb 4
2020;94(5):e439-e452. doi:10.1212/wnl.0000000000008881
18.   Association between brain imaging signs, early and late outcomes, and response
to intravenous alteplase after acute ischaemic stroke in the third International Stroke
Trial (IST-3): secondary analysis of a randomised controlled trial. *Lancet Neurol*. May
2015;14(5):485-96. doi:10.1016/s1474-4422(15)00012-5
448